Arkolith/Insider Trading/COAG/Form 4

Ra Capital Management, L.P.

Director, 10% OwnerHemab Therapeutics Holdings, Inc. (COAG) · full profile →Form 4 · filed May 6, 2026
Net Buying
Open-Market Buys
$52.2M
Open-Market Sells
$0
Net Open-Market Flow
$52.2M
Transactions
15
9 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 6, 2026Buy(P)15K$23.77$347K6.3M
May 6, 2026Buy(P)53K$24.83$1.3M6.3M
May 5, 2026Buy(P)87K$24.59$2.1M6.2M
May 5, 2026Buy(P)10K$25.00$257K6.2M
May 4, 2026Buy(P)134K$18.00$2.4M355K
May 4, 2026Conversion(C)3.6M——3.6M
May 4, 2026Conversion(C)1.0M——1.0M
May 4, 2026Conversion(C)221K——221K
May 4, 2026Buy(P)2.5M$18.00$45.7M6.1M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 4, 2026Conversion(C)65K——0
May 4, 2026Conversion(C)28K——0
May 4, 2026Conversion(C)42K——0
May 4, 2026Conversion(C)18K——0
May 4, 2026Conversion(C)57K——0
May 4, 2026Conversion(C)10K——0

Transaction Codes

P
Open-market purchase
C
Conversion of a derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001231919-26-000457) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML